MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Nov. 18, 2021--
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer.
“Jonathan brings to PhaseBio deep commercial expertise in the critical-care setting, which he gained through his leadership of the thrombolytics franchise at Genentech,” said Jonathan P. Mow, Chief Executive Officer of PhaseBio. “With his background and track record of success, Jonathan has the experience necessary to lead our commercial organization and joins us at a pivotal time in PhaseBio’s evolution as we begin preparing to launch bentracimab in the United States, should it be approved by the U.S. Food and Drug Administration (FDA).”
Jonathan has over 25 years of experience in the biopharmaceuticals industry, including building and leading commercial teams in the United States and the United Kingdom. He joins PhaseBio after 12 years at Genentech where, most recently, he was Vice President and U.S. Head of the company’s thrombolytics franchise. Prior to this role, Jonathan was Lifecycle Leader for the global launch of Kadcyla® and also served as Marketing Director and National Sales Director in the respiratory franchise. Before joining Genentech, Jonathan worked at Sanofi Aventis for 15 years, initially as a sales representative in the United Kingdom before taking on numerous commercial roles with increasing responsibility including Global Marketing Director, and ultimately serving as Business Unit Head in the U.K.
Jonathan will lead PhaseBio’s efforts to build a critical-care focused commercial organization to support the U.S. launch of bentracimab. The company is targeting to submit its Biologics License Agreement with the FDA in mid-2022 , which, if approved, could position U.S. launch of bentracimab in early 2023.
“I am excited to join PhaseBio’s executive team with a focus on building out the company’s commercial organization in the U.S.,” said Mr. Birchall. “The data we have seen to date from the bentracimab clinical development program appears quite compelling from a safety and efficacy perspective, with adverse events considered related to bentracimab reported in only a few patients to date, and we believe the product is positioned well to address what remains a significant unmet need. It’s a critical time to join the team as we pivot to prepare for commercial launch of bentracimab in the U.S. Our focus will be on supporting our customers, ensuring broad availability of bentracimab and helping to serve the millions of patients on ticagrelor globally who could benefit from the potentially life-saving restoration of platelet function that bentracimab provides.”
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.
PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “potential,” “projects,” “target,” “will,” “would” and “future” or similar expressions are intended to identify forward-looking statements.
Forward-looking statements include statements concerning the potential for bentracimab to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, the expected timing of regulatory submissions and potential commercial launch of bentracimab and whether, if approved, bentracimab will be successfully distributed, marketed and commercialized. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.
Risks regarding our business are described in detail in our Securities and Exchange Commission filings, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. These forward-looking statements speak only as of the date hereof, and PhaseBio Pharmaceuticals, Inc. disclaims any obligation to update these statements except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118006306/en/
PhaseBio Pharmaceuticals, Inc.
Chief Financial Officer
Canale Communications, Inc.
Source: PhaseBio Pharmaceuticals, Inc.